Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 3 4Phase 2 3

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2NET 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 2Neuroendocrine Tumors 1Neoplasms 1

Interventions

Cisplatin 1514Carboplatin 1416Cyclophosphamide 1359Gemcitabine 1235Bevacizumab 1223Paclitaxel 1210Radiotherapy 1173Docetaxel 1079pembrolizumab 1026Oxaliplatin 934Capecitabine 898Fluorouracil 832Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 665Etoposide 660Irinotecan 622Leucovorin 574Pemetrexed 508Drug Therapy 491Cetuximab 481Trastuzumab 467Cytarabine 466Magnetic Resonance Spectroscopy 457Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 407Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Interventional × AMG 757 × Clear all
NCT06502977 2026-04-15

DeLLphi-307

Amgen

Phase 2 Active not recruiting
32 enrolled 9 charts
EndocrineNET

Neoplasms, Neuroendocrine Tumors

NCT06745323 2026-03-03

DeLLphi-309

Amgen

Phase 2 Active not recruiting
252 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT07423585 2026-02-20

Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
39 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡